FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2281421996> ?p ?o ?g. }

• W2281421996 endingPage "456" @default.
• W2281421996 startingPage "456" @default.
• W2281421996 abstract "456 Background: Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) inhibitors showed activity in mRCC and are currently in development in first-line and previously treated patients (pts). Whether these drugs will modify efficacy of subsequent targeted therapy (TT) including VEGFR tyrosine kinase inhibitors (TKI) or mTOR inhibitors is unknown. Methods: Medical records of RCC patients treated with investigational PD-1 or PD-L1 inhibitors who received subsequent treatment with TT were reviewed in 4 institutions. Baseline characteristics at the time of subsequent therapy and outcome data including time to treatment failure (TTF), best response, 1 and 2 year overall survival (OS) were retrospectively collected. Results: Of 89 pts who received PD-1/PD-L1 inhibitors, 56 patients (M/F 39/17, clear-cell 53, IMDC good 3/intermediate 16/poor 11/unknown 26) have received a subsequent therapy after PD-1/PD-L1 blockade, while 7 patients are still on therapy and 26 patients did not receive subsequent therapy. Among these 26 patients, 12 died from disease and 14 are still alive off-systemic therapies. 43 pts received VEGFR TKI and 13 received mTOR inhibitors as first subsequent TT. Median follow up from start of the subsequent TT is 16.1 months (range: 0.2, 30.6 months). TT post PD-1/PD-L1 was administered as second line in 9 patients (16%), third line in 24 patients (43%), > fourth line in 23 patients (41%). Median TTF was 6.9 months (range: 0.2+, 23.0), and was 6.9 and 5.7 months in patients who received VEGFR TKI and mTOR inhibitors respectively. One-year and 2-year OS from the initiation of subsequent TT was 58% (95% CI: 41-72%) and 36% (95% CI: 18%-54%), respectively. Investigator-assessed best response to subsequent TT was evaluated in 53 out of 56 patients: PR (n=7, 13%), SD (n=33, 62 %), and PD (n=13, 25%). Conclusions: This is the first report of TT efficacy after PD-1/PD-L1 inhibition. In this selected population, median TTF suggests a sustained benefit of both VEGFR TKI and mTOR inhibitors after PD-1/PDL1 inhibition." @default.
• W2281421996 created "2016-06-24" @default.
• W2281421996 creator A5007052233 @default.
• W2281421996 creator A5024766386 @default.
• W2281421996 creator A5028242882 @default.
• W2281421996 creator A5037646183 @default.
• W2281421996 creator A5049672639 @default.
• W2281421996 creator A5052504518 @default.
• W2281421996 creator A5054850662 @default.
• W2281421996 creator A5066816851 @default.
• W2281421996 creator A5074162105 @default.
• W2281421996 creator A5077071889 @default.
• W2281421996 date "2015-03-01" @default.
• W2281421996 modified "2023-10-17" @default.
• W2281421996 title "Efficacy of targeted therapies after PD1/PD-L1 inhibitors in metastatic clear cell renal cell carcinoma (mRCC): A multi-institution retrospective cohort." @default.
• W2281421996 doi "https://doi.org/10.1200/jco.2015.33.7_suppl.456" @default.
• W2281421996 hasPublicationYear "2015" @default.
• W2281421996 type Work @default.
• W2281421996 sameAs 2281421996 @default.
• W2281421996 citedByCount "0" @default.
• W2281421996 crossrefType "journal-article" @default.
• W2281421996 hasAuthorship W2281421996A5007052233 @default.
• W2281421996 hasAuthorship W2281421996A5024766386 @default.
• W2281421996 hasAuthorship W2281421996A5028242882 @default.
• W2281421996 hasAuthorship W2281421996A5037646183 @default.
• W2281421996 hasAuthorship W2281421996A5049672639 @default.
• W2281421996 hasAuthorship W2281421996A5052504518 @default.
• W2281421996 hasAuthorship W2281421996A5054850662 @default.
• W2281421996 hasAuthorship W2281421996A5066816851 @default.
• W2281421996 hasAuthorship W2281421996A5074162105 @default.
• W2281421996 hasAuthorship W2281421996A5077071889 @default.
• W2281421996 hasConcept C121608353 @default.
• W2281421996 hasConcept C126322002 @default.
• W2281421996 hasConcept C141071460 @default.
• W2281421996 hasConcept C143998085 @default.
• W2281421996 hasConcept C167135981 @default.
• W2281421996 hasConcept C2776694085 @default.
• W2281421996 hasConcept C2777472916 @default.
• W2281421996 hasConcept C2780775027 @default.
• W2281421996 hasConcept C2781230642 @default.
• W2281421996 hasConcept C71924100 @default.
• W2281421996 hasConcept C72563966 @default.
• W2281421996 hasConcept C90924648 @default.
• W2281421996 hasConceptScore W2281421996C121608353 @default.
• W2281421996 hasConceptScore W2281421996C126322002 @default.
• W2281421996 hasConceptScore W2281421996C141071460 @default.
• W2281421996 hasConceptScore W2281421996C143998085 @default.
• W2281421996 hasConceptScore W2281421996C167135981 @default.
• W2281421996 hasConceptScore W2281421996C2776694085 @default.
• W2281421996 hasConceptScore W2281421996C2777472916 @default.
• W2281421996 hasConceptScore W2281421996C2780775027 @default.
• W2281421996 hasConceptScore W2281421996C2781230642 @default.
• W2281421996 hasConceptScore W2281421996C71924100 @default.
• W2281421996 hasConceptScore W2281421996C72563966 @default.
• W2281421996 hasConceptScore W2281421996C90924648 @default.
• W2281421996 hasIssue "7_suppl" @default.
• W2281421996 hasLocation W22814219961 @default.
• W2281421996 hasOpenAccess W2281421996 @default.
• W2281421996 hasPrimaryLocation W22814219961 @default.
• W2281421996 hasRelatedWork W1997102106 @default.
• W2281421996 hasRelatedWork W2057935885 @default.
• W2281421996 hasRelatedWork W2137381953 @default.
• W2281421996 hasRelatedWork W2316933016 @default.
• W2281421996 hasRelatedWork W2319453831 @default.
• W2281421996 hasRelatedWork W2394541713 @default.
• W2281421996 hasRelatedWork W2396139388 @default.
• W2281421996 hasRelatedWork W2791305060 @default.
• W2281421996 hasRelatedWork W2899960064 @default.
• W2281421996 hasRelatedWork W2949270765 @default.
• W2281421996 hasVolume "33" @default.
• W2281421996 isParatext "false" @default.
• W2281421996 isRetracted "false" @default.
• W2281421996 magId "2281421996" @default.
• W2281421996 workType "article" @default.